Neurocrine Biosciences starts Phase 1 trial of NBIP-'2118, a novel obesity drug preserving muscle mass.

Neurocrine Biosciences has initiated a Phase 1 clinical trial to test NBIP-'2118, a new drug targeting the CRF 2 receptor for obesity treatment. This investigational therapy aims to reduce fat while preserving or increasing lean muscle mass, addressing a key limitation of current weight loss drugs. The trial will assess safety and tolerability in healthy and overweight adults, with initial results expected in 2027. Neurocrine is also developing combination therapies to enhance weight loss effects while maintaining muscle preservation.